A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Jiangsu Cancer Institute & Hospital
National Cancer Institute (NCI)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Centre Oscar Lambret
Neonc Technologies, Inc.
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)